A clearer approach to weight care.Explore Aero

GLP-1 treatment and gallstones: the risk, the signs, the prevention

Laboratory corridor

Rapid weight loss raises gallstone risk regardless of method. What to know, what to watch, and how to lower the odds.

The warning signs #

  • Pain in the upper right abdomen, often after a fatty meal, sometimes reaching the back or right shoulder
  • Pain with fever or chills
  • Yellowing of skin or eyes (jaundice)
  • Pale stools or dark urine

Pain alone: prompt GP or 111 assessment. Pain with fever or jaundice: urgent care the same day.

Lowering the odds #

  • A steady pace of loss, 0.5 to 1 kg a week, rather than the fastest possible descent.
  • Not skipping meals for long stretches. The gallbladder needs to empty regularly.
  • Some dietary fat at meals (a little olive oil, oily fish) keeps bile moving, low-fat diets paradoxically raise risk.

If you have had gallbladder problems #

Tell us in the health check. Past gallstones or gallbladder removal do not automatically rule out GLP-1 treatment, but they shape the conversation, including whether a slower titration makes sense for you.

Continue reading

Know the warning signsSevere stomach pain, swelling of your face or throat, or trouble breathing need emergency care. Read when to get urgent help for who to call.

Understand your treatment options

Explore the treatment guides and prepare your questions for a clinician. Aero’s prices and service details will be confirmed before booking opens.

See all plans

Page information

Summary
GLP-1 and gallstones: why rapid weight loss raises risk, the warning signs, prevention tactics, and what past gallbladder problems mean. Read Aero’s guide.
Publisher
Aero Clinic, operated by AERO HEALTHCARE LTD.
Editorial update
Clinical review
Pending. An editorial update is not a clinical sign-off.

Cite as: GLP-1 treatment and gallstones: the risk, the signs, the prevention, Aero Clinic (https://www.cagri.co.uk), AERO HEALTHCARE LTD. https://www.cagri.co.uk/gallstones. Editorial update: 4 November 2026. Clinical review pending.

Explore your options